Aytu BioPharma, Inc. (AYTU) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Aytu BioPharma, Inc. (AYTU) Healthcare & Pipeline Overview

Aytu BioPharma, Inc. develops and commercializes specialty pharmaceuticals, primarily focusing on ADHD treatments and other therapeutics. With a portfolio including Adzenys XR-ODT and Tuzistra XR, Aytu operates in a competitive market, balancing growth opportunities with financial constraints and a negative profit margin.

What Is the Investment Thesis for AYTU?

Aytu BioPharma, Inc. presents a high-risk, high-reward investment profile. The company's focus on specialty pharmaceuticals, particularly ADHD treatments, offers growth potential in a market with increasing demand. Key value drivers include successful commercialization of existing products like Adzenys XR-ODT and Tuzistra XR, as well as potential acquisitions of complementary products. However, the company's negative profit margin of -39.0% and negative free cash flow of $-0.01B raise concerns about its financial sustainability. The company's market capitalization is approximately $0.02B, and it operates with a beta of 0.28. Upcoming catalysts include potential regulatory approvals for new formulations or indications. Investors should closely monitor Aytu's ability to improve profitability and manage its debt. The P/E ratio is -50.00.

Based on FMP financials and quantitative analysis

AYTU Key Highlights

• Market Cap of $17.5M indicates a small-cap company with potential for high growth but also higher risk.
• Gross Margin of 66.0% suggests strong pricing power and efficient cost management in its product lines.
• Negative Profit Margin of -39.0% highlights significant challenges in achieving profitability and managing operating expenses.
• Free Cash Flow of $-0.01B indicates the company is currently burning cash and may need additional financing.
• P/E Ratio of -50.00 reflects negative earnings, indicating the company is not currently profitable.

Who Are AYTU's Competitors?

AYTU is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AYTU's Key Strengths?

• Portfolio of established products in niche markets.
• Proprietary formulations for key products.
• Experienced management team.
• Focus on addressing unmet medical needs.

What Are AYTU's Weaknesses?

• Negative profit margin.
• Negative free cash flow.
• High debt levels.
• Reliance on a limited number of key products.

What Could Drive AYTU Stock Higher?

• Potential regulatory approvals for new formulations or indications for existing products.
• Continued commercialization efforts for key products like Adzenys XR-ODT and Tuzistra XR.
• Strategic acquisitions of complementary products or companies.

What Are the Key Risks for AYTU?

• Financial-distress signal — its Altman Z-Score of -4.56 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Competition from established pharmaceutical companies and generic alternatives.
• Regulatory challenges and delays in product approvals.
• High debt levels and negative cash flow.
• Reliance on a limited number of key products.

What Are the Growth Opportunities for AYTU?

• Expansion of ADHD Product Line: Aytu can expand its market share within the ADHD treatment space by developing new formulations, dosages, or delivery methods for its existing products like Adzenys XR-ODT and Cotempla XR-ODT. The ADHD market is projected to reach $20 billion by 2028, offering significant revenue potential. Successful product line expansion could drive revenue growth and improve profitability.
• Strategic Acquisitions: Aytu can pursue strategic acquisitions of complementary products or companies to broaden its portfolio and diversify its revenue streams. Targeting companies with established products in related therapeutic areas, such as allergy or sleep disorders, could create synergies and enhance Aytu's market position. The timeline for acquisitions depends on available capital and target availability.
• International Expansion: Aytu can expand its geographic reach by entering new international markets. Focusing on regions with growing healthcare spending and unmet medical needs, such as Asia or Latin America, could drive revenue growth and reduce reliance on the U.S. market. International expansion requires regulatory approvals and market entry strategies, with a potential timeline of 2-3 years.
• Development of Novel Therapeutics: Aytu can invest in the research and development of novel therapeutics to address unmet medical needs. Focusing on innovative treatments for chronic diseases or rare disorders could create high-value products with strong market potential. The development of new therapeutics is a long-term process, with a timeline of 5-10 years.
• Direct-to-Consumer Marketing: Aytu can enhance its brand awareness and drive sales by implementing direct-to-consumer (DTC) marketing campaigns. Targeting patients and caregivers through online advertising, social media, and educational materials could increase demand for its products. DTC marketing requires careful compliance with regulatory guidelines and ethical considerations, with an ongoing timeline for implementation.

What Opportunities Does AYTU Have?

• Expansion of ADHD product line.
• Strategic acquisitions of complementary products.
• International expansion.
• Development of novel therapeutics.

What Threats Does AYTU Face?

• Competition from established pharmaceutical companies.
• Generic erosion of key products.
• Regulatory challenges.
• Product liability risks.

What Are AYTU's Competitive Advantages?

• Proprietary formulations for certain products.
• Established brand recognition for key products like Adzenys XR-ODT.
• Distribution network for reaching healthcare providers and patients.

What Does AYTU Do?

Aytu BioPharma, Inc., established in 2015 and headquartered in Englewood, Colorado, is a specialty pharmaceutical company dedicated to the development and commercialization of novel therapeutics and consumer healthcare products. The company's core focus lies in addressing unmet medical needs through innovative treatments and solutions. Aytu's portfolio includes a range of products targeting various therapeutic areas, including attention deficit hyperactivity disorder (ADHD), allergies, and sleep disorders. Key products include Adzenys XR-ODT, a treatment for ADHD in patients aged 6 and older; Cotempla XR-ODT, another ADHD medication for patients aged 6 to 17; and Adzenys ER, an oral suspension for ADHD treatment. Additionally, Aytu offers Karbinal ER, an oral suspension for treating seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor, prescription supplements for infants and children; Tuzistra XR, an antitussive for cough relief; and ZolpiMist, an oral spray for insomnia. Formerly known as Aytu BioScience, Inc., the company rebranded in March 2021 to reflect its evolving strategic direction and expanded product offerings. Aytu distributes its products across the United States and internationally, aiming to provide accessible and effective healthcare solutions to a diverse patient population. The company operates with a team of 102 employees.

What Products and Services Does AYTU Offer?

• Develop and commercialize specialty pharmaceutical products.
• Offer Adzenys XR-ODT for the treatment of ADHD in patients 6 years and older.
• Provide Cotempla XR-ODT for ADHD treatment in patients aged 6 to 17.
• Market Adzenys ER, an oral suspension for ADHD treatment.
• Offer Karbinal ER for the treatment of seasonal and perennial allergies.
• Provide Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children.
• Market Tuzistra XR, an antitussive for cough relief.
• Offer ZolpiMist, an oral spray for the treatment of insomnia.

How Does AYTU Make Money?

• Develop and acquire specialty pharmaceutical products.
• Commercialize products through sales and marketing efforts.
• Generate revenue through product sales in the United States and internationally.

What Industry Does AYTU Operate In?

Aytu BioPharma operates within the specialty pharmaceutical industry, a segment characterized by its focus on niche markets and specialized treatments. The industry is driven by innovation, regulatory approvals, and market demand for targeted therapies. The competitive landscape includes both large pharmaceutical companies and smaller, specialized players. Aytu's focus on ADHD treatments positions it in a growing market, but it faces competition from established brands and generic alternatives. The overall pharmaceutical market is expected to continue growing, driven by an aging population and increasing healthcare spending.

Who Are AYTU's Key Customers?

• Patients with ADHD.
• Patients with allergies.
• Patients with insomnia.
• Infants and children requiring fluoride supplements.

FY2026 estForward Outlook

Wall Street analysts project Aytu BioPharma, Inc. revenue of about $53.7M for fiscal 2026, with EPS near $-1.06.

Quarterly Financial Performance: Aytu BioPharma, Inc.

Revenue for Aytu BioPharma, Inc. came in at $12.4M during Q1 2026, a 18.2% contraction versus the preceding quarter. The company recorded a net loss of $5.6M, with diluted EPS of $-0.53. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, AYTU averaged $-1.14 in diluted EPS.

AYTU Valuation & Market Position

With a $17.5M market cap, Aytu BioPharma, Inc. sits in the micro-cap segment of the market. Relative to its peer group, AYTU's quantitative score of 21/100 is below the peer average of 56/100.

Key Financial Metrics

Return on assets is -30.5%, showing how much profit it generates from its asset base. Its free cash flow yield is 9.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.12 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -144.6%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

Aytu BioPharma, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.56 places it in the distress zone, a signal of elevated financial risk.

Company Profile

Aytu BioPharma, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Englewood, US. The company is led by CEO Joshua R. Disbrow. AYTU has traded publicly since 2008.

AYTU Financials

AYTU Latest News

AYTU Analyst Consensus

AYTU MoonshotScore

Latest Aytu BioPharma, Inc. Analysis

What Investors Ask About Aytu BioPharma, Inc. (AYTU) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources